H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $14
AngioDynamics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target
Buy Rating Affirmed for AngioDynamics Following Positive Trial Outcomes and Market Expansion Potential
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Argenx Se (ARGX) and AngioDynamics (ANGO)
HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target
AngioDynamics Analyst Ratings
AngioDynamics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target
Buy Rating on AngioDynamics: Growth and Regulatory Approvals Underscore Positive Outlook
AngioDynamics Analyst Ratings
Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential
Analysts' Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Raymond James Maintains Outperform on AngioDynamics, Lowers Price Target to $10
AngioDynamics Analyst Ratings
Oppenheimer Keeps Their Hold Rating on AngioDynamics (ANGO)
HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18
AngioDynamics Analyst Ratings
Buy Rating Maintained for AngioDynamics Amidst Strategic Restructuring and New Product Launches